News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Analyst recommends buying Opera (OPRA).
  • Opera offers a 5.29% dividend and trades near 12x P/E and 1.3x book value.
  • Technicals show constructive momentum and falling short interest; suggested trade: entry $15.04, stop $13.50, target $18.50.
  • Senior U.S. and Iranian officials met in Pakistan to discuss ending the six-week conflict.
  • Pope Leo urged an end to the 'madness of war' and called for dialogue over rearmament.
  • U.S.-Iran talks and the pope's appeal could ease geopolitical risk and support risk-on market flows.

Latest Articles

Coeur Mining: The Pullback Is Overdone — Tactical Long Into Recovery

Coeur Mining: The Pullback Is Overdone — Tactical Long Into Recovery

Coeur Mining (CDE) has retraced sharply despite stronger cash flow, a manageable balance sheet and a meaningful production boost from the New Gold acquisition. A tactical long at $17.50 with a $15.90 stop targets $22.00 over the next ~45 trading days, playing for a recovery to the 50-day technical band and re-rating driven by buybacks, dividend ini…

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting

InflaRx N.V. reported Phase 3 clinical data for vilobelimab in pyoderma gangrenosum (PG) featured at the 2026 American Academy of Dermatology Annual Meeting. The study was terminated early for futility but showed promising trends in clinical remission and ulcer healing compared to placebo, alongside a favorable safety profile. InflaRx plans to enga…

Buy PRCT on the Dip: A Patient Long on Robotic Urology Growth

Buy PRCT on the Dip: A Patient Long on Robotic Urology Growth

PROCEPT BioRobotics (PRCT) is a commercial-stage surgical robotics company focused on Aquablation for BPH. The stock trades at $26.49 with a $1.49B market cap after a February guidance cut and a subsequent wave of negative headlines. Fundamentals show rapid prior top-line growth, a strong liquidity position, and an EV/sales ratio that can compress …

Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026

Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026

Can-Fite BioPharma announced that its veterinary partner Vetbiolix has completed enrollment in a Phase 2 clinical trial testing Piclidenoson for osteoarthritis in dogs. Data is expected in Q3 2026. Vetbiolix has exercised its option to fully license Piclidenoson for veterinary use, with Can-Fite eligible for up to $325 million in payments subject t…

Investors Flock to U.S. Dividend Funds as Risk and Rate Uncertainty Rise

Investors Flock to U.S. Dividend Funds as Risk and Rate Uncertainty Rise

U.S. dividend income funds have seen heavy inflows so far this year, drawing $24.1 billion in net new money and marking the strongest first quarter in four years, according to LSEG Lipper data. Investors and wealth managers cite geopolitical tensions, elevated oil prices linked to the Iran conflict, and a turbulent bond market as reasons for reallo…

Avis Budget Shares Slide After Filing for Equity Distribution Agreement

Avis Budget Shares Slide After Filing for Equity Distribution Agreement

Avis Budget Group disclosed an Equity Distribution Agreement dated March 27, 2026, allowing the company to offer up to 5,000,000 common shares through ten sales agents. The announcement, which details at-the-market sales or other permitted methods and a sales commission cap of 2.00%, preceded a 10% decline in the company's stock on Monday.

Palo Alto Networks Shares Jump After CEO Buys $10 Million in Stock

Palo Alto Networks Shares Jump After CEO Buys $10 Million in Stock

Palo Alto Networks stock climbed roughly 2% in premarket trading after CEO Nikesh Arora disclosed a $10 million open-market purchase of company shares. The disclosure followed a broader sell-off in cybersecurity names triggered by reports that AI startup Anthropic was testing an advanced model with cybersecurity features and that related details we…

Jefferies Elevates DSV to Top Pick as Freight Rates Show Improvement

Jefferies Elevates DSV to Top Pick as Freight Rates Show Improvement

DSV shares gained after Jefferies upgraded the Danish logistics group to its top pick while keeping a Buy rating, pointing to improving freight rate conditions in air and sea transport that should support yields and the company’s full-year guidance. Jefferies also maintained a Buy on DHL and expects DSV to discuss AI-related opportunities and risks…

Starcloud's Funding Boost Values Orbital AI Bid at $1.1 Billion

Starcloud's Funding Boost Values Orbital AI Bid at $1.1 Billion

Starcloud has secured $170 million in fresh funding at a $1.1 billion valuation to accelerate development of orbital compute infrastructure, backing plans for a large satellite data-center constellation and commercial operations. The round, led by Benchmark and EQT Ventures, follows industry moves by other space ventures and highlights investor app…

Airbus Helicopters sees higher oil prices reviving H225 Super Puma demand

Airbus Helicopters sees higher oil prices reviving H225 Super Puma demand

Airbus Helicopters' departing chief executive said surging oil prices may encourage renewed offshore investment and help the redesigned H225 Super Puma regain market share a decade after a fatal rotor-blade separation grounded the type. While some regions have embraced the updated H225, North Sea operators remain cautious. The executive also outlin…

Hazama Ando Lifts Profit Forecast After Stronger Building-Margin Performance

Hazama Ando Lifts Profit Forecast After Stronger Building-Margin Performance

Hazama Ando has increased its earnings guidance for the fiscal year ending March 2026, citing a stronger-than-expected margin profile in its building construction business and one-off gains from the sale of cross-shareholdings. The company raised operating profit and net profit targets, confirmed its civil engineering margin view, unveiled a new mi…

Monarch Cement: Easy Gains Behind Us, But a Clean Path Higher Remains

Monarch Cement: Easy Gains Behind Us, But a Clean Path Higher Remains

Monarch Cement (MCEM) has already delivered a nice run from its 2025 low, but the company’s sub-$1B market cap, modest PE of 14.3, and concrete exposure to U.S. infrastructure spending leave a constructive setup. The trade is long with defined risk - target near the 52-week high and a stop below structurally important support. Liquidity is low and …

CareCloud Highlights Successful Preferred A Conversion, Progress Toward Capital Structure Simplification, and Reaffirms Growth Outlook

CareCloud Highlights Successful Preferred A Conversion, Progress Toward Capital Structure Simplification, and Reaffirms Growth Outlook

CareCloud, Inc. announced the successful conversion of its Series A Preferred Stock into common equity, increasing outstanding common shares substantially. The company reported stable stock performance since the conversion and reaffirmed its financial guidance and growth prospects. Despite a contained cybersecurity incident affecting one of its EHR…

Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network

Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network

Hope Therapeutics, a subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), announced a strategic partnership with Emobot Health to deploy its AI-driven 'Depression Thermometer' across a network of interventional psychiatry clinics. This passive monitoring tool uses AI to analyze facial expressions, vocal tones, and activity data via smartphones to dete…